The 33 rating InvestorsObserver gives to REDHILL BIOPHAR/S ADR (RDHL) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 23 percent of stocks in the Biotechnology industry, RDHLs 33 overall rating means the stock scores better than 33 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 33 means the stock is more attractive than 33 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

REDHILL BIOPHAR/S ADR (RDHL) stock has risen 3.51% while the S&P 500 is down -1.37% as of 11:31 AM on Tuesday, Feb 25. RDHL has gained $0.16 from the previous closing price of $4.70 on volume of 405,326 shares. Over the past year the S&P 500 is up 13.79% while RDHL is down -37.56%. RDHL earned $0.26 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 18.71.

To see the top 5 stocks in Biotechnology click here.

See the original post here:
How Does REDHILL BIOPHAR/S ADR (RDHL) Stock Compare to Other Stocks in Biotechnology? - InvestorsObserver